Company intelligence / Profile preview
GenEdit
South San Francisco / Brisbane, California, United Statesgenedit.com ↗
- Ownership
- Private
- Employees
- ~45
- Development stage
- Preclinical
01
Overview
GenEdit has not publicly disclosed clinical results. The company’s lead programs are in the discovery/preclinical stage. Its platform has demonstrated potential for tissue-selective and flexible payload delivery with low immunogenicity and re-dosing capability.
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- Lipid nanoparticle delivery therapyPolymer nanoparticle delivery therapyGene therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Sarepta Therapeutics – up to $57 million for gene-editing therapeutics targeting neuromuscular diseasesEli Lilly – investment and collaboration on gene-editing/gene-delivery technology development
Beyond the preview
Go deeper on GenEdit.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GenEdit.